BioWorld

Nov. 11, 2008

View Archived Issues

ArQule Makes Two Deals with Daiichi in Cancer

ArQule would receive $75 million in up-front cash under two deals with Japan's Daiichi Sankyo Co. Ltd. - one to develop an anticancer compound and the other to discover a new generation of kinase inhibitors for cancer. (BioWorld Today) Read More

LDL Hypothesis Alive and Well; Other Biomarkers also Valuable

Read More

Improved T-Cell Receptor Takes on all Comers of HIV Epitope

Read More

Moving from Licensing Talks to M&A can be a Tricky Step

Read More

Regulatory Hitch to Delay Solzira Filing, Milestone to XenoPort

Read More

Other News To Note

Read More

Financings Roundup

Read More

Clinic Roundup

Read More